scholarly journals Quantitative Evaluation of the In Vivo Vocal Fold Medial Surface Shape

2017 ◽  
Vol 31 (4) ◽  
pp. 513.e15-513.e23 ◽  
Author(s):  
Andrew M. Vahabzadeh-Hagh ◽  
Zhaoyan Zhang ◽  
Dinesh K. Chhetri
2005 ◽  
Vol 115 (9) ◽  
pp. 1646-1654 ◽  
Author(s):  
Michael Doellinger ◽  
David A. Berry ◽  
Gerald S. Berke

PLoS ONE ◽  
2020 ◽  
Vol 15 (7) ◽  
pp. e0236348
Author(s):  
Naila Cannes do Nascimento ◽  
Andrea P. dos Santos ◽  
M. Preeti Sivasankar ◽  
Abigail Cox
Keyword(s):  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ryosuke Nakamura ◽  
Nao Hiwatashi ◽  
Renjie Bing ◽  
Carina P. Doyle ◽  
Ryan C. Branski

AbstractVocal fold (VF) fibrosis is a major cause of intractable voice-related disability and reduced quality of life. Excision of fibrotic regions is suboptimal and associated with scar recurrence and/or further iatrogenic damage. Non-surgical interventions are limited, putatively related to limited insight regarding biochemical events underlying fibrosis, and downstream, the lack of therapeutic targets. YAP/TAZ integrates diverse cell signaling events and interacts with signaling pathways related to fibrosis, including the TGF-β/SMAD pathway. We investigated the expression of YAP/TAZ following vocal fold injury in vivo as well as the effects of TGF-β1 on YAP/TAZ activity in human vocal fold fibroblasts, fibroblast-myofibroblast transition, and TGF-β/SMAD signaling. Iatrogenic injury increased nuclear localization of YAP and TAZ in fibrotic rat vocal folds. In vitro, TGF-β1 activated YAP and TAZ in human VF fibroblasts, and inhibition of YAP/TAZ reversed TGF-β1-stimulated fibroplastic gene upregulation. Additionally, TGF-β1 induced localization of YAP and TAZ in close proximity to SMAD2/3, and nuclear accumulation of SMAD2/3 was inhibited by a YAP/TAZ inhibitor. Collectively, YAP and TAZ were synergistically activated with the TGF-β/SMAD pathway, and likely essential for the fibroplastic phenotypic shift in VF fibroblasts. Based on these data, YAP/TAZ may evolve as an attractive therapeutic target for VF fibrosis.


2015 ◽  
Vol 126 (1) ◽  
pp. E12-E17 ◽  
Author(s):  
Abigail Durkes ◽  
M. Preeti Sivasankar
Keyword(s):  

2019 ◽  
Vol 25 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Sanzhar Askaruly ◽  
Yujin Ahn ◽  
Hyeongeun Kim ◽  
Andrey Vavilin ◽  
Sungbea Ban ◽  
...  

1976 ◽  
pp. 230-231
Author(s):  
G. S. Dimitrievich ◽  
S. L. Hausladen ◽  
F. T. Kuchnir ◽  
M. L. Griem

2019 ◽  
Author(s):  
Vlasta Lungova ◽  
Susan Thibeault

Abstract Development of treatments for vocal dysphonia has been inhibited by lack of human vocal fold (VF) mucosa models because of difficulty in procuring VF epithelial cells, epithelial cells’ limited proliferative capacity and absence of cell lines. We report development of engineered VF mucosae from hiPSC, transfected via TALEN constructs for green fluorescent protein, that mimic development of VF epithelial cells in utero. Modulation of FGF signaling achieves stratified squamous epithelium from definitive and anterior foregut derived cultures. Robust culturing of these cells on collagen-fibroblast constructs produces three-dimensional models comparable to in vivo VF mucosa.


Sign in / Sign up

Export Citation Format

Share Document